首页> 美国卫生研究院文献>other >A Comparison of Intralesional Triamcinolone Acetonide Injection for Primary Chalazion in Children and Adults
【2h】

A Comparison of Intralesional Triamcinolone Acetonide Injection for Primary Chalazion in Children and Adults

机译:曲安奈德乙内酯注射液用于儿童和成人初治Ch嗪的比较。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Purpose. To investigate outcome differences of intralesional triamcinolone acetonide (TA) injection for primary chalazia in children versus adults. Methods. A retrospective review of consecutive subjects with primary chalazion who received intralesional TA injection was conducted. A single investigator injected 0.05–0.15 mL of TA (40 mg/mL) intralesionally. Patients were stratified into the pediatric (<18 years old) and adult (≥18 years old) group. In both groups, the correlation of resolution time with chalazion size and TA dose was performed. Results. 17 children and 24 adults were enrolled, with a mean age of 7.4 ± 5.5 and 39.3 ± 16.7 years, respectively. Both groups had statistically similar baseline characteristics. There was no significant difference between the resolution time in the pediatric (18.2 ± 11.4 days) and adult (16.5 ± 11.0 days) group (P = 0.7). There were no significant complications from the TA injection. There was no significant correlation of resolution time to chalazion size (P = 0.7) nor TA dose (P = 0.3) in both groups. Conclusion. TA for the treatment of primary chalazion was equally effective in children and adults, without any significant complications, and the rate of clinical response did not appear to be dose-dependent.
机译:目的。目的调查儿童内和成人间皮内注射曲安奈德(TA)对原发性黄褐斑的疗效差异。方法。回顾性研究了连续的原发性cha虫病患者接受病灶内TA注射的情况。一名研究者经皮内注射0.05–0.15µmL TA(40µmg / mL)。将患者分为儿科(<18岁)和成人(≥18岁)组。在两组中,均进行了拆分时间与螯合物大小和TA剂量的相关性。结果。入组的儿童分别为17名儿童和24名成人,平均年龄分别为7.4±5.5和39.3±16.7岁。两组均具有统计学上相似的基线特征。小儿(18.2±11.4天)和成人(16.5±11.0天)组的分辨时间之间无显着差异(P = 0.7)。 TA注射没有明显的并发症。两组的拆分时间与cha大小(P = 0.7)和TA剂量(P = 0.3)均无显着相关性。结论。 TA在儿童和成人中治疗原发性睑板腺炎同样有效,没有任何重大并发症,并且临床反应率似乎与剂量无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号